{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-152323","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.282900+00:00","generated_at":"2026-06-01T06:43:21.614825+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edwards Lifesciences sells Critical Care unit to BD for $4.2B cash, ends spin-off","bullets":["All-cash sale of Critical Care product group to BD (NYSE: BDX) valued at $4.2 billion.","Edwards will no longer pursue the previously announced spin-off of Critical Care.","Transaction expected to close by end of 2024; impact to 2024 adjusted EPS immaterial.","Critical Care will remain in Irvine, CA, led by current corporate VP Katie Szyman.","After-tax cash proceeds to fund strategic structural heart innovation investments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-152323","json":"https://secwatch.observer/filing/0001193125-24-152323.json","markdown":"https://secwatch.observer/filing/0001193125-24-152323.md","text":"https://secwatch.observer/filing/0001193125-24-152323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000119312524152323/0001193125-24-152323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000119312524152323/d836710d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:43:21.614825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}